Lutathera Radioligand Therapy
Lutathera® (Lutetium Lu 177 Dotatate)
Peptide receptor radionuclide therapy (PRRT) for somatostatin receptor–positive neuroendocrine tumors
Overview
Lutathera is a targeted radiopharmaceutical therapy for neuroendocrine tumors that express somatostatin receptors. It combines the somatostatin analog dotatate with lutetium-177. The drug binds predominantly to somatostatin receptor subtype 2 on tumor cells and delivers beta radiation to receptor-expressing disease.
FDA Approval and Who May Benefit
Lutathera was FDA-approved in 2018 for adults with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors. In 2024, the indication was expanded to include pediatric patients 12 years of age and older with SSTR-positive GEP-NETs.
Why This Therapy Is Useful
PRRT provides systemic, receptor-targeted treatment for patients whose tumors demonstrate sufficient somatostatin-receptor expression on DOTATATE PET imaging. It is particularly valuable for patients with unresectable or metastatic well-differentiated neuroendocrine tumors when systemic treatment is indicated.
What to Expect / Typical Protocol
- Before treatment: Eligibility is confirmed using somatostatin-receptor imaging (typically Ga-68 DOTATATE PET/CT or equivalent), pathology, prior treatment history, blood counts, renal and hepatic function, and clinical assessment.
- Treatment: The standard FDA-labeled regimen is 7.4 GBq (200 mCi) intravenously every 8 weeks for a total of 4 doses, with modifications when clinically indicated.
- Kidney protection: An intravenous amino-acid solution is administered with therapy to reduce radiation dose to the kidneys. Antiemetic medication is typically given before the amino-acid infusion.
- Somatostatin analog management: Timing of short- and long-acting somatostatin analogs is coordinated with the treatment team to avoid interference with receptor targeting.
- Monitoring and follow-up: Blood counts, kidney function, liver function, symptoms, tumor markers when appropriate, and follow-up imaging are reviewed during and after therapy.
Refer a Patient for Radioligand Therapy (Lutathera®)
The Division of Nuclear Medicine at UTHealth Houston offers comprehensive evaluation and treatment with Lutathera® (Lutetium Lu 177 Dotatate) for eligible patients with somatostatin receptor–positive neuroendocrine tumors
Our multidisciplinary team provides:
- Comprehensive eligibility assessment
- Imaging review and treatment planning
- Coordination of laboratory testing and scheduling
- Administration of radioligand therapy
- Post-treatment imaging and follow-up in collaboration with the referring oncologist
How to Refer:
Community oncologists and other healthcare providers may refer patients by:
- Faxing the referral and relevant clinical records to: 713-704-1360
- Emailing one of our Nuclear Medicine faculty members by selecting a physician profile above.
Please include, when available:
- Recent clinic note
- Pathology reports
- Relevant imaging reports (including DOTATATE PET/CT, if performed)
- Recent laboratory results (CBC, CMP, renal and liver function tests)
- Current medication list and prior cancer treatments
Our team will promptly review the referral, contact the patient if appropriate, and coordinate consultation and treatment while maintaining close communication with the referring physician throughout the patient’s care.